MMSI Stock Down Despite Latest Positive Data From WRAPSODY WAVE Trial

Zacks11-27

Merit Medical Systems, Inc. MMSI announced positive six-month findings from the single-arm Arteriovenous Graft (AVG) cohort of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial yesterday...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486884102?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/x7AJ0AkRL_CYuqXFyPb2BQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5","is_english":true,"pubTime":"2024-11-27 00:02","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486884102","market":"us","top_or_hot":-1,"title":"MMSI Stock Down Despite Latest Positive Data From WRAPSODY WAVE Trial","media":"Zacks","content":"<div>\n<p>Merit Medical Systems, Inc. MMSI announced positive six-month findings from the single-arm Arteriovenous Graft (AVG) cohort of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial yesterday...</p>\n\n<a href=\"https://finance.yahoo.com/news/mmsi-stock-down-despite-latest-160200185.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MMSI Stock Down Despite Latest Positive Data From WRAPSODY WAVE Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMMSI Stock Down Despite Latest Positive Data From WRAPSODY WAVE Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-27 00:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mmsi-stock-down-despite-latest-160200185.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merit Medical Systems, Inc. MMSI announced positive six-month findings from the single-arm Arteriovenous Graft (AVG) cohort of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial yesterday...</p>\n\n<a href=\"https://finance.yahoo.com/news/mmsi-stock-down-despite-latest-160200185.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0128525689.USD","symbol_name":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/mmsi-stock-down-despite-latest-160200185.html","article_id":"2486884102","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/x7AJ0AkRL_CYuqXFyPb2BQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486884102","pubTimestamp":1732636920,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Merit Medical Systems, Inc. MMSI announced positive six-month findings from the single-arm Arteriovenous Graft  cohort of its WRAPSODY Arteriovenous Access Efficacy  pivotal trial yesterday. The WAVE trial was designed to assess the efficacy and safety of the WRAPSODY device.The WRAPSODY Cell-Impermeable Endoprosthesis is currently not approved or available for commercial distribution in the United States. It may also not be approved or available for sale or use in other countries. However, the device is available in Brazil and in the European Union.In the United States, the device is being used under an Investigational Device Exemption from the FDA. Per management, the findings from the WAVE trial expand on results from the first-in-human trial  and support the premarket approval application to the FDA for commercial use in the United States.The announcement of the latest favorable findings from the WAVE pivotal trial is a significant stepping stone for Merit Medical, which is likely ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4082":"医疗保健设备","MMSI":"Merit Medical Systems","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","BK4588":"碎股","BK4198":"医疗保健用品","BK4084":"特种房地产投资信托","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","BK4133":"新能源发电业者","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","WAVE":"Eco Wave Power Global AB (publ)","GMED":"Globus Medical Inc","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","CAH":"卡地纳健康","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","BK4529":"IDC概念","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","BK4175":"保健护理产品经销商","BK4539":"次新股","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","COR":"CENCORA","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4585":"ETF&股票定投概念","LU0566484027.USD":"安本美国小盘成长股","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD"},"translate_title":"尽管WRAPSODY WAVE试验的最新积极数据，MMSI股价仍下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WAVE":1,"MMSI":1,"COR":1,"GMED":1,"CAH":0.9},"content_text":"Merit Medical Systems, Inc. MMSI announced positive six-month findings from the single-arm Arteriovenous Graft (AVG) cohort of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial yesterday. The WAVE trial was designed to assess the efficacy and safety of the WRAPSODY device.\nThe WRAPSODY Cell-Impermeable Endoprosthesis is currently not approved or available for commercial distribution in the United States. It may also not be approved or available for sale or use in other countries. However, the device is available in Brazil and in the European Union.\nIn the United States, the device is being used under an Investigational Device Exemption from the FDA. Per management, the findings from the WAVE trial expand on results from the first-in-human trial (WRAPSODY FIRST) and support the premarket approval application to the FDA for commercial use in the United States.\nThe announcement of the latest favorable findings from the WAVE pivotal trial is a significant stepping stone for Merit Medical, which is likely to strengthen its foothold in the global hemodialysis space.\nLikely Trend of MMSI Stock Following the News\nFollowing the announcement on Nov. 25, shares of the company lost nearly 0.4% at yesterday’s closing.\nHistorically, the company has gained a high level of synergies from its various product launches and positive trial outcomes. Although the announcement of the latest favorable findings from the WAVE pivotal trial is likely to be beneficial for MMSI’s top-line growth going forward, the stock declined overall despite a slight gain till Friday.\nMerit Medical currently has a market capitalization of $6.12 billion. Its projected earnings per share growth of 11.6% is higher than the industry’s 7.5%. In the last reported quarter, MMSI delivered an earnings surprise of 7.5%.\nSignificance of Merit Medical’s Positive Trial Outcome\nAn AVG is a synthetic tube that is used for long-term access to blood vessels for patients undergoing hemodialysis. However, over time, the graft may become narrow or blocked, resulting in potentially life-threatening consequences. Per management, Merit Medical’s WRAPSODY Cell-Impermeable Endoprosthesis has been designed to restore and extend vessel access (patency) in hemodialysis patients, which is critical for patient survival.\nPer an expert associated with the trial, given the historically low patency rates for AVG patients, the favorable results from the AVG arm of the WAVE trial are encouraging for physicians who manage these patients.\nMerit Medical has been collaborating with physician partners to improve care for hemodialysis patients, and expanded its product offering and focus on these patients. The WRAPSODY device is an important part of this growing portfolio.\nIndustry Prospects in Favor of MMSI\nPer a report by Allied Market Research, the global hemodialysis market was valued at $76.9 billion in 2022 and is anticipated to reach $111.8 billion by 2032 at a CAGR of 3.8%. Factors like the growing awareness regarding hemodialysis and the increasing prevalence of chronic cardiac diseases and end-stage renal disease are likely to drive the market.\nGiven the market potential, the latest announcement of a positive trial outcome is expected to solidify Merit Medical’s foothold in the niche space.\nMerit Medical’s Notable Development\nIn September, MMSI announced positive six-month findings from the randomized arteriovenous fistula arm of its WRAPSODY WAVE pivotal trial. The data were shown at the Cardiovascular and Interventional Radiological Society of Europe.\nMMSI’s Share Price Performance\nShares of the company have gained 46.2% in the past year compared with the industry’s 9.1% rise and the S&P 500's 31.6% growth.\nImage Source: Zacks Investment Research\nMerit Medical’s Zacks Rank & Other Key Picks\nCurrently, MMSI carries a Zacks Rank #2 (Buy).\nA few other top-ranked stocks in the broader medical space are Cardinal Health, Inc. CAH, Cencora, Inc. COR and Globus Medical, Inc. GMED.\nCardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 11.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nCardinal Health’s shares have gained 14.4% compared with the industry’s 9.1% rise in the past year.\nCencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.1%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average being 6.9%.\nCencora has gained 21% against the industry’s 1% decline in the past year.\nGlobus Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.1%. GMED’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.7%.\nGlobus Medical’s shares have rallied 82.9% compared with the industry’s 15.1% rise in the past year.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCardinal Health, Inc. (CAH) : Free Stock Analysis Report\nMerit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report\nCencora, Inc. (COR) : Free Stock Analysis Report\nGlobus Medical, Inc. (GMED) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486884102"}